Biological Lattice Industries Secures Pre-Seed Funding

Biological Lattice Industries Corp. (BLI) has closed a $1.8 million pre-seed investment round led by Greek venture capital firm Uni.Fund.

“We are thrilled to partner with Uni.Fund to bring our vision of democratizing biofabrication to life,” BLI Founder/CEO Filippos Tourlomousis. “This funding will allow us to accelerate the development of our unified platform, enabling researchers to work with greater precision, reproducibility, and efficiency.”

In conjunction with the funding announcement, the company also is introducing its first all-in-one solution for biofabrication: BioLoom, an advanced multi-tool 3D bioprinter, and Loominus Studio, a unified software platform that aims to revolutionize biofabrication workflows.

A U.S. startup with R&D operations in Greece, BLI is striving to simplify biofabrication for the global R&D community by providing intelligent, automated tools that streamline biomaterial design, fabrication, and testing. Biomaterials are critical for numerous biological applications ranging from advanced 3D cell culture systems for human biology emulation to next-generation of resorbable medical devices and drug delivery systems for tissue trauma repair.

Loominus Studio: A Unified Platform for Biofabrication

Current biofabrication workflows often require the coordination of multiple protocols, parameters and instruments, none of which are integrated. Loominus Studio, BLI’s software offering, integrates every aspect of the biofabrication workflow, from design to fabrication. This all-in-one solution allows researchers to automate complex workflows, improving reproducibility and reducing the effort required to optimize biofabrication processes.

“Loominus Studio represents a new standard in biofabrication, allowing labs to focus on innovation rather than the technical challenges of integration,” Tourlomousis stated. “Our goal is to make biofabrication as simple and intuitive as possible, empowering researchers to break through technical barriers.”

BioLoom: Beyond Basic Bioprinting

At the core of BLI’s growing tool ecosystem is BioLoom, a versatile multi-tool extrusion-based 3D bioprinter that can fabricate high-resolution multi-material architected scaffolds and devices. With its Active Environmental Control feature, BioLoom ensures reproducibility and supports Good Manufacturing Practice (GMP) compliance, making it ideal for labs focused on accelerating commercialization in life sciences.

“BioLoom provides an unparalleled level of versatility and precision,” Tourlomousis noted. “It is designed to meet the needs of both academic and commercial labs, pushing the boundaries of biofabrication beyond traditional 3D bioprinting capabilities.”

With its vision, BLI is working to establish Loominus as the industry standard for biofabrication labs, offering a continuously growing array of tools and features that simplify complex workflows. The investment will accelerate the market availability of BioLoom and Loominus Studio that have already deployed to leading academic labs through the company’s early adopter’s customer program.

Uni.Fund, a venture capital firm committed to supporting deep tech startups in Europe, considers BLI a transformative force in biofabrication. “BLI is a game-changer in the biotech space, with a bold vision to disrupt how biofabrication is performed globally,” Uni.Fund Founding Partner Katerina Pramatari said. “Their integrated approach to life sciences R&D, combining sophisticated hardware and software powered by AI, is exactly the kind of innovation that Uni.Fund aims to support.”

Biological Lattice Industries Corp. is a venture-backed startup founded in 2021 to democratize biofabrication for life sciences R&D. BLI’s platform, Loominus Studio, and its ecosystem of integrated hardware tools, including the BioLoom bioprinter, aim to alter the way biomaterials are designed, fabricated, and tested.